Shionogi & Co., Ltd. TSE:4507

Shionogi : Agreement on the Absorption-Type Split of JT Pharmaceutical Division and Acquisition of Shares of Akros, and Commencement of Tender Offer for TORII

Published

Source: MarketScreener

Agreement on the Absorption-Type Split of JT Pharmaceutical Division and Acquisition of Shares of Akros, and Commencement of Tender Offer for TORII

May 7, 2025

1

Shionogi & Co., Ltd



SHIONOGI's Vision

Building Innovation Platforms to Shape the Future of Healthcare

SHIONOGI Group Vision (2030 Vision)



- What we want to achieve by 2030 -

Continuously enhance our " strengths" as a drug-discovery-oriented pharma company, become the premier partner for other companies/industries for its unique strengths,

build new platforms in the healthcare arena

STS2030 Revision

Achieve 2030 Vision as a HaaS* company

Realizing our transformation Growth from transformation

STS Phase3 ('26 - '30)

STS Phase2

('23 -'25)

STS Phase1

('20 -'22)





2 * Healthcare as a Service: Provide a range of healthcare services in line with customer needs, rather than only providing pharmaceuticals

SHIONOGI's Unique Growth Strategy



SHIONOGI's growth strategy

Growth strategy of pharmaceutical companies through acquisitions

Strengthening Research Capabilities

Innovative

In-House Product Development

Venture Company A

Venture

Acquisitions through Reinvestment of Profits

Pharmaceutical Company

Providing

Reinvestment in Research and Development

Ensuring High profitability

Company B

Academia

Strengthening pipeline and expanding regions through acquisitions

New Drugs

3

Providing new drugs globally based on superior research capabilities that foster innovation Acquiring innovation externally through acquisitions, promoting development, and providing new drugs

4

Further Evolving the Business Model by Returning to "the Basics of Pharmaceutical Business Model = In-House Drug Discovery"


Strengthening Points for Achieving our 2030 Vision

Achieving our 2030 Vision through a business stabilization and strengthening R&D capabilities

  • Stabilization of the infectious disease business

    • Improvement of COVID-19 treatment rates through expanded information provision

  • Introduction of domestic product assets that are not influenced by epidemics

    • Establishment of high social impact QOL (Quality of Life) disease areas

  • Strengthening of the supply chain system

Business stabilization

Launching new products for QOL diseases and expanding promotional activities

  • Strengthening the research foundation

  • Further enhancing our capabilities in small molecule drug discovery

  • Further reinforcing the infectious disease field and acquiring the next pillar

Strengthening R&D capabilities

Drug discovery of globally competitive in-house products





5